12 Month Price Forecast For ENFN
Distance to ENFN Price Forecasts
ENFN Price Momentum
🤔 Considering Enfusion (ENFN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 3:09 AM UTC
ENFN Analyst Ratings & Price Targets
Based on our analysis of 10 Wall Street analysts, ENFN has a consensus that is neutral. The median price target is $11.25, with forecasts ranging from $9.64 to $11.25. Currently, there are 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
With ENFN currently trading at $11.16, the median price forecast suggests a 0.8% upside. The most optimistic forecast comes from at , projecting a 0.8% upside, while at provides the most conservative target, suggesting a -13.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENFN Analyst Consensus
ENFN Price Target Range
Latest ENFN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENFN.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 13, 2025 | William Blair | Bhavan Suri | Market Perform | Downgrade | $0.00 |
Dec 23, 2024 | Piper Sandler | Neutral | Maintains | $0.00 | |
Dec 18, 2024 | Stifel | Buy | Maintains | $0.00 | |
Mar 13, 2024 | B of A Securities | Koji Ikeda | Underperform | Maintains | $9.00 |
Feb 28, 2024 | Goldman Sachs | Gabriela Borges | Sell | Downgrade | $8.00 |
Jan 30, 2024 | JP Morgan | Alexei Gogolev | Underweight | Downgrade | $9.00 |
Dec 20, 2023 | Piper Sandler | Sumeet Mody | Neutral | Maintains | $10.00 |
Nov 7, 2023 | UBS | Kevin Mcveigh | Neutral | Initiates | $9.00 |
Aug 9, 2023 | Morgan Stanley | James Faucette | Overweight | Maintains | $11.00 |
Aug 9, 2023 | Goldman Sachs | Gabriela Borges | Neutral | Maintains | $10.00 |
May 22, 2023 | Piper Sandler | Sumeet Mody | Neutral | Maintains | $9.00 |
May 10, 2023 | Credit Suisse | Kevin Mcveigh | Neutral | Maintains | $11.00 |
Apr 3, 2023 | Piper Sandler | Sumeet Mody | Neutral | Initiates | $11.00 |
Mar 15, 2023 | JP Morgan | Alexei Gogolev | Neutral | Initiates | $12.00 |
Jan 26, 2023 | Goldman Sachs | Gabriela Borges | Neutral | Maintains | $9.50 |
Jan 4, 2023 | B of A Securities | Koji Ikeda | Underperform | Downgrade | $10.00 |
Jan 3, 2023 | Morgan Stanley | James Faucette | Overweight | Upgrade | $12.00 |
Oct 3, 2022 | B of A Securities | Koji Ikeda | Neutral | Downgrade | $15.00 |
Aug 10, 2022 | Morgan Stanley | James Faucette | Equal-Weight | Maintains | $13.00 |
Jul 14, 2022 | Goldman Sachs | Gabriela Borges | Neutral | Maintains | $12.00 |
Stocks Similar to Enfusion, Inc.
The following stocks are similar to Enfusion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enfusion, Inc. (ENFN) Financial Data
Enfusion, Inc. has a market capitalization of $1.06B with a P/E ratio of 279.5x. The company generates $195.16M in trailing twelve-month revenue with a 1.7% profit margin.
Revenue growth is +15.4% quarter-over-quarter, while maintaining an operating margin of +5.8% and return on equity of +5.5%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Enfusion, Inc. (ENFN) Company Overview
About Enfusion, Inc.
Provides SaaS solutions for investment management.
Enfusion, Inc. operates on a software-as-a-service (SaaS) model, offering a suite of solutions tailored for the investment management industry. The company generates revenue by providing its Portfolio Management System, Order and Execution Management System, and Accounting/General Ledger System, among other tools, which help financial professionals manage portfolios, execute trades, and comply with regulations.
Founded in 1997 and headquartered in Chicago, Illinois, Enfusion serves clients across the United States, Europe, the Middle East, Africa, and the Asia Pacific. Its services include technology-driven solutions and managed services, which enhance operational efficiency for investment firms.
Company Information
Sector
Technology
Industry
Software - Application
Employees
1,102
CEO
Mr. Oleg Movchan
Country
United States
IPO Year
2021
Website
www.enfusion.comEnfusion, Inc. (ENFN) Latest News & Analysis
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. (NYSE:ENFN) and Clearwater Analytics. Investors are encouraged to seek more information on the firm's site.
Merger investigations can signal potential risks or changes in a company's valuation, affecting stock performance and investor sentiment regarding Enfusion and Clearwater Analytics.
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. (NYSE:ENFN) and Clearwater Analytics, urging current investors to seek more information.
The investigation into Enfusion's merger could signal potential legal or regulatory issues, impacting stock performance and investor sentiment toward Enfusion and Clearwater Analytics.
Bronstein, Gewirtz & Grossman is investigating Enfusion, Inc.'s merger with Clearwater Analytics. Investors holding Enfusion shares are encouraged to participate in the inquiry.
The investigation into Enfusion's merger with Clearwater Analytics may impact stock performance and governance, affecting shareholder value and investment decisions.
Schall Law Firm is investigating potential fiduciary duty breaches by Enfusion, Inc. (NYSE:ENFN) directors and management, raising concerns for investors.
The investigation into Enfusion's board for potential fiduciary breaches could lead to legal ramifications, affecting shareholder value and market perception.
The Schall Law Firm is investigating potential fiduciary duty breaches by the board of Enfusion, Inc. (NYSE:ENFN), which may impact shareholder interests.
The investigation into Enfusion's board for potential fiduciary breaches could impact shareholder value and trust, influencing stock performance and investor sentiment.
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. (NYSE:ENFN) and Clearwater Analytics. Current investors are urged to seek more information.
The investigation into the Enfusion-Clearwater merger may indicate potential legal or regulatory issues, impacting stock performance and investor confidence in Enfusion.
Frequently Asked Questions About ENFN Stock
What is Enfusion, Inc.'s (ENFN) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Enfusion, Inc. (ENFN) has a median price target of $11.25. The highest price target is $11.25 and the lowest is $9.64.
Is ENFN stock a good investment in 2025?
According to current analyst ratings, ENFN has 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ENFN stock?
Wall Street analysts predict ENFN stock could reach $11.25 in the next 12 months. This represents a 0.8% increase from the current price of $11.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enfusion, Inc.'s business model?
Enfusion, Inc. operates on a software-as-a-service (SaaS) model, offering a suite of solutions tailored for the investment management industry. The company generates revenue by providing its Portfolio Management System, Order and Execution Management System, and Accounting/General Ledger System, among other tools, which help financial professionals manage portfolios, execute trades, and comply with regulations.
What is the highest forecasted price for ENFN Enfusion, Inc.?
The highest price target for ENFN is $11.25 from at , which represents a 0.8% increase from the current price of $11.16.
What is the lowest forecasted price for ENFN Enfusion, Inc.?
The lowest price target for ENFN is $9.64 from at , which represents a -13.6% decrease from the current price of $11.16.
What is the overall ENFN consensus from analysts for Enfusion, Inc.?
The overall analyst consensus for ENFN is neutral. Out of 10 Wall Street analysts, 0 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $11.25.
How accurate are ENFN stock price projections?
Stock price projections, including those for Enfusion, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.